2025 · 2nd Quarter (Apr 1 - June 30)

JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES

Filed by MARSHALL & POPP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 21, 2025
Income: $40,000.00
Expenses: Not reported
Registrant: MARSHALL & POPP, LLC
Client: JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES
Filing UUID: e191ed89-5b31-4706-871e-ab313ccc9079
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14.

Literal federal measure citations: H.Con.Res. 14

HCR · Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R. 4121, FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.

Literal federal measure citations: H.R. 1, H.R. 4121, H.R.946

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.